Loading...
Protagenic Therapeutics, Inc.
PTIXW•NASDAQ
Healthcare
Biotechnology
$0.06
$0.010(19.60%)
Protagenic Therapeutics, Inc. (PTIXW) Stock Overview
Explore Protagenic Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for PTIXWStats details for PTIXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PTIXWAnalyst Recommendations details for PTIXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
CEO
Dr. Garo H. Armen Ph.D.
Employees
1
Headquarters
149 Fifth Avenue, New York City, NY
Founded
2021